Date: 2017-02-20
Type of information: Commercialisation agreement
Compound: Zoladex® (goserelin acetate implant)
Company: AstraZeneca (UK) TerSera Therapeutics (USA)
Therapeutic area: Cancer - Oncology - Women health
Type agreement: commercialisation
Action mechanism: GnRH analog. Zoladex® (goserelin acetate implant) is a synthetic analog of gonadotropin-releasing hormone (GnRH) that acts as potent inhibitor of pituitary gonadotropin secretion.
Disease: prostate cancer, breast cancer, benign gynaecological disorders
Details: * On February 20, 2017, AstraZeneca announced that it has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex® (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders. It was first approved in the US and Canada in 1989.
In 2016, product sales for Zoladex® were $69 million in the US and Canada, and $816 million globally. AstraZeneca will continue to commercialise Zoladex® in all markets outside the US and Canada. The transaction is expected to complete in the first quarter of 2017, subject to customary closing conditions. The agreement does not include the transfer of any AstraZeneca employees or facilities and does not impact AstraZeneca’s financial guidance for 2017.
Financial terms: TerSera will pay AstraZeneca $250 million upon completion. AstraZeneca will also receive sales-related income through milestones totalling up to $70 million, as well as recurring quarterly sales-based payments at mid-teen percent of Product Sales. AstraZeneca will also manufacture and supply Zoladex to TerSera, providing a further source of ongoing income from Zoladex in the US and Canada.
Latest news:
